加载中
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
前收盘价
US$2.82
−US$0.12 · -4.08%
盘后
US$2.97
+US$0.15 · +5.32%
10月12日 19:37 ET
盘中时间采用ET。市场数据可能有所延迟。
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
日内区间
当前US$2.82
52周区间
当前US$2.82
盘中时间采用ET。市场数据可能有所延迟。
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
日内区间
当前US$2.82
52周区间
当前US$2.82
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 276.32万 USD | 608.34万 USD | 385.92万 USD | 691.08万 USD | 632.81万 USD |
| 销售、一般及管理费用 | 1200.85万 USD | 931.01万 USD | 1320.46万 USD | 1598.14万 USD | 2337万 USD |
| 营业费用 | 1530.24万 USD | 1613.63万 USD | 2378.95万 USD | 2742.96万 USD | 3374.37万 USD |
| 利息收入 | 23.61万 USD | 57.29万 USD | 78.64万 USD | 36.77万 USD | 1292 USD |
| 利息支出 | 61.86万 USD | 4.76万 USD | 299 USD | 4.88万 USD | 6.94万 USD |
| 折旧和摊销 | 54.58万 USD | 49.06万 USD | 250.63万 USD | 453.46万 USD | 404.55万 USD |
| 营业利润 | −1530.24万 USD | −1613.63万 USD | −2378.95万 USD | −2742.96万 USD | −3374.37万 USD |
| 净利润 | −2617.53万 USD | −1420.27万 USD | −1790.22万 USD | −2360.68万 USD | −3528.54万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
